Waters beat Q2 earnings estimates on both EPS and revenue, demonstrated strong organic growth of 9% in constant currency, successfully integrated acquired businesses exceeding guidance, raised full-year 2026 guidance, and showed broad-based momentum across all divisions with improving margins and strong free cash flow generation.
Articles that tag WAT but are mainly about other companies.
Listed as a key competitor in the growing laboratory informatics market, with exposure to expanding demand for integrated data management and workflow automation solutions.
Listed as a leading market player in the mass spectrometry market, which is experiencing strong growth driven by pharmaceutical manufacturing and clinical diagnostics adoption.
Listed among key market players in a sector experiencing robust growth due to increased clinical trials, biopharmaceutical innovations, and demand for equipment maintenance services.
Received BD's Biosciences and Diagnostic Solutions business through spin-off completed February 9, 2026. Mentioned as recipient of high-margin business segment but no specific performance data or outlook provided in article.
Waters is mentioned in context of the planned combination with the separated Biosciences and Diagnostic Solutions businesses from Becton Dickinson, but no specific performance data or analyst commentary about Waters itself is provided in the article.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
